Merck chief doubles down on 'good cholesterol' drug

Even as failures in the field pile up, Merck ($MRK) CEO Kenneth Frazier is pushing ahead with a massive development program for a drug to boost HDL or "good" cholesterol. And despite growing doubts about the prospects for such treatments, he appears to see the risky bet worth the potential payoff. Report